1. Academic Validation
  2. HECT, UBA and WWE domain containing 1 represses cholesterol efflux during CD4+ T cell activation in Sjögren's syndrome

HECT, UBA and WWE domain containing 1 represses cholesterol efflux during CD4+ T cell activation in Sjögren's syndrome

  • Front Pharmacol. 2023 Jun 26:14:1191692. doi: 10.3389/fphar.2023.1191692.
Junhao Yin 1 2 3 4 Jiabao Xu 1 2 3 4 Changyu Chen 1 2 3 4 Xinyi Ma 1 2 3 4 Hanyi Zhu 1 2 3 4 Lisong Xie 1 2 3 4 Baoli Wang 1 2 3 4 Yanxiong Shao 1 2 3 4 Yijie Zhao 5 Yu Wei 6 Anni Hu 6 Zhanglong Zheng 6 Chuangqi Yu 1 2 3 4 Jiayao Fu 1 2 3 4 Lingyan Zheng 1 2 3 4
Affiliations

Affiliations

  • 1 Department of Oral Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, Shanghai, China.
  • 2 National Center for Stomatology and National Clinical Research Center for Oral Disease, Shanghai, China.
  • 3 Shanghai Key Laboratory of Stomatology, Shanghai, China.
  • 4 Shanghai Institute of Stomatology, Shanghai, China.
  • 5 Department of Oral and Maxillofacial Surgery, Shanghai Stomatological Hospital, Fudan University, Shanghai, China.
  • 6 Department of Oral and Maxillofacial Surgery, Shanghai Engineering Research Center of Tooth Restoration and Regeneration, School and Hospital of Stomatology, Tongji University, Shanghai, China.
Abstract

Introduction: Sjögren's syndrome (SS) is a chronic autoimmune disorder characterized by exocrine gland dysfunction, leading to loss of salivary function. Histological analysis of salivary glands from SS patients reveals a high infiltration of immune cells, particularly activated CD4+ T cells. Thus, interventions targeting abnormal activation of CD4+ T cells may provide promising therapeutic strategies for SS. Here, we demonstrate that Hect, uba, and wwe domain containing 1 (HUWE1), a member of the eukaryotic Hect E3 ubiquitin Ligase family, plays a critical role in CD4+ T-cell activation and SS pathophysiology. Methods: In the context of HUWE1 inhibition, we investigated the impact of the HUWE1 inhibitor BI8626 and sh-Huwe1 on CD4+ T cells in mice, focusing on the assessment of activation levels, proliferation capacity, and Cholesterol abundance. Furthermore, we examined the therapeutic potential of BI8626 in NOD/ShiLtj mice and evaluated its efficacy as a treatment strategy. Results: Inhibition of HUWE1 reduces ABCA1 ubiquitination and promotes Cholesterol efflux, decreasing intracellular Cholesterol and reducing the expression of phosphorylated ZAP-70, CD25, and Other activation markers, culminating in the suppressed proliferation of CD4+ T cells. Moreover, pharmacological inhibition of HUWE1 significantly reduces CD4+ T-cell infiltration in the submandibular glands and improves salivary flow rate in NOD/ShiLtj mice. Conclusion: These findings suggest that HUWE1 may regulate CD4+ T-cell activation and SS development by modulating ABCA1-mediated Cholesterol efflux and presents a promising target for SS treatment.

Keywords

ABCA1; CD4+ T cell; HUWE1; Sjögren’s syndrome; cholesterol efflux.

Figures
Products